Now Reading:
Celgene Corporation Names Second Round of Celgene Cancer Care Links™ Program Grant Recipients
Full Article 6 minutes read

Celgene Corporation Names Second Round of Celgene Cancer Care Links™ Program Grant Recipients

Grants include additional geographies, areas of focus and disease targets

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced an additional ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support healthcare capacity building in resource-constrained countries around the world. The program and initial grants were announced in December 2018.

The Celgene Cancer Care Links program is an activity of Celgene Global Health, which focuses on healthcare challenges facing patients in developing parts of the world. Programs support established institutions partnering with in-country medical centers that provide essential health and cancer care services including awareness and education, prevention, diagnosis and care.

“Celgene Cancer Care Links continues to provide critical support to organizations that are shaping healthcare practice in resource-constrained countries,” said Mark J. Alles, Chairman and Chief Executive Officer of Celgene. “Programs like this are the reason Celgene Global Health is such an important part of what we do for patients each day.”

Recipients of Celgene Cancer Care Links grants include:


Program Title


Partner Institution

Stroke Prevention in Children with Sickle Cell Anemia

Cincinnati Children’s Hospital, Cincinnati, OH

Bugando Medical Centre, Tanzania

Promoting Healthy Lives and Well-Being by Improving Access To and Quality of Pediatric Oncology Services in Myanmar

World Child Center, London, UK

Yangon Children’s Hospital, Mandalay Children’s Hospital, Myanmar

Implementing and Evaluating a Palliative Wound Care and Palliative Care Nursing Educational Program at Ocean Road Cancer Institute

University of California, San Francisco, CA

Ocean Road Cancer Institute, Tanzania

Development and Evaluation of a National Protocol to Treat Pediatric Acute Lymphoblastic Leukemia in Vietnam

University of Texas, San Antonio, TX

University of Medicine and Pharmacy, Vietnam

Improving Cancer Care by Improving Pathology Services

INCTR, University of Basel, Switzerland

Tikur Anbessa Hospital, Addis Abada, Ethiopia

A Joint Pediatric Hem-Onc Specialty Nursing and Pharmacy Training Program for Capacity Building in Lilongwe, Malawi

Baylor College of Medicine, Houston, TX

Baylor College of Medicine Children’s Foundation – Malawi

Strengthening Clinical Capacity and Patient Navigation at Belize’s First Public Oncology Program

Global Oncology, Brookline, MA

Karl Heusner Memorial Hospital, Belize

Optimizing Nephroblastoma Treatment Outcomes in Ugandan Children

Fred Hutchinson Cancer Research Center, Seattle, WA

Hutchinson Centre Research Institute, Uganda

Promoting Education and Awareness of Pediatric Cancer in Botswana

Baylor College of Medicine, Houston, TX

Botswana Baylor Children’s Clinical Centre, Botswana

Building a Culture of Care Quality Improvement at Butaro Cancer Center of Excellence in Rwanda

Dana-Farber Cancer Institute, Boston, MA

Butaro Cancer Center, Rwanda


“As the Celgene Cancer Care Links program progresses, we are pleased to see programs from new geographies and in new areas of disease participating,” said Joe Camardo, M.D., Senior Vice President, Global Health and Corporate Affairs Medical Strategy at Celgene. “These programs continue to be an important channel for healthcare capacity building in resource-constrained nations.”

About Celgene Cancer Care Links™

Celgene Cancer Care Links is a grant program to support health care capacity initiatives that enhance patient cancer care in resource-constrained countries. Celgene Cancer Care Links is a demonstration of Celgene’s commitment to improving the lives of patients worldwide.

The Celgene Cancer Care Links program is also featured in Access Accelerated, a group of over 20 biopharmaceutical companies developing innovative and sustainable solutions to improve access to non-communicable disease treatment and care in low and middle-income countries. In addition to each company committing to do more with their individual programs, Access Accelerated also includes partnerships with the World Bank and the Union of International Cancer Control. Access Accelerated is part of the private sector’s commitment to achieving the United Nations Sustainable Development Goal target to reduce premature deaths from NCDs by 2030.

For more information on these programs, as well as Celgene’s Corporate Responsibility and Global Health efforts, please visit the following links:

To read our latest Corporate Responsibility report, please visit

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit Follow Celgene on Social Media: @Celgene, LinkedIn and Facebook.


This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission, including factors related to the proposed transaction between Bristol-Myers Squibb and Celgene, such as, but not limited to, the risks that: management’s time and attention is diverted on transaction related issues; disruption from the transaction make it more difficult to maintain business, contractual and operational relationships; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company that could delay or prevent the proposed transaction; and Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel.

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

All trademarks are the property of their respective owners.


Celgene Corporation





Leave a Reply

Your email address will not be published. Required fields are marked *

Input your search keywords and press Enter.